Clinical Trial Update: Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating APL-130277 for acute treatment of OFF episodes in Parkinson's disease completed with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• APL-130277 (APL-130277)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Parkinson Disease, Off Episodes | Phase 3 | Status: COMPLETED | Results posted: 2020-07-30